Stock Taper 
| DATE | TYPE | RATIO |
|---|---|---|
| 2026-04-16 | Reverse | 1:6 |
| 2021-04-01 | Reverse | 1:3 |
NeuroOne Medical Technologies develops thin film electrode technology for neurological recording, stimulation, and ablation, targeting epilepsy, Parkinson's, pain, and other disorders, with a strategic partnership for RF ablation solutions.
The OneRF Ablation System by NeuroOne is a radiofrequency device for creating lesions in nervous tissue for neurosurgical procedures, marking the company's first therapeutic device with its first implant in April 2024.
NeuroOne Medical Technologies announced a staggering 907% year-over-year increase in product revenue for the fourth quarter of fiscal 2025, reaching $2.7 million. For the full fiscal year, product revenue grew 163% to $9.1 million, accompanied by a significant improvement in gross margins and a 71% reduction in net loss. This exceptional financial performance, driven by the commercialization of its OneRF ablation system, positioned fiscal year 2025 as the most successful in the company's history and led to a notable positive reaction in its stock price.
In 2025, NeuroOne Medical Technologies Corporation's most significant strategic shift was the leveraging and expansion of its exclusive distribution agreement with Zimmer Biomet. This partnership was the primary driver of a 163% increase in year-over-year product revenue and included a significant $3 million license revenue payment, marking a pivotal move to aggressively scale commercialization and enter new therapeutic areas like pain management. [1, 15, 18]
What happened NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) said preliminary fourth-quarter product revenue was $3.8 million. That was up 38.4% from $2.7 million a year earlier. The company also said full-year product revenue should be about $10.5 million. That would put it at the top of guidance and up 15.6% from the prior year. In
Preliminary Fiscal Q4 2026 Product Revenue of $3.8 Million Preliminary Full-Year Product Revenue Up 15.6% to $10.5 Million, at the Top of Guidance Range EDEN PRAIRIE, Minn., Oct. 05, 2026 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, today announced preliminary, unaudited product revenue for its fourth fiscal quarter and full fiscal year ended September 30, 2026, and provided an update on recent product orders.
NeuroOne Medical Technologies (NASDAQ: NMTC - Get Free Report) and Innovative Eyewear (NASDAQ: LUCY - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, risk, earnings, dividends and valuation. Valuation and Earnings This table compares
$10 Million in New Markets Tax Credit Financing for a New cold Storage and Refrigerated Logistics Facility in Albertville, ALPR NewswireATMORE, Ala., Oct. 2, 20
Overall rating: D+
| PEER | PRICE | |
|---|---|---|
 ECOR | $9.57 | COMPARE |
 ATHE | $3.34 | COMPARE |
 MYO | $1.39 | COMPARE |
 HYPD | $3.27 | COMPARE |
 STRR | $10.06 | COMPARE |
 BDMD | $0.77 | COMPARE |
 YI | $3.09 | COMPARE |
 CTSO | $3.75 | COMPARE |
